Brief: Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020
18/12/2023 12:40
Dec 18 (Reuters) - Lexeo Therapeutics Inc LXEO.O :
* LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION AND
ORPHAN
DRUG DESIGNATION FOR LX2020, AN AAV-BASED GENE THERAPY CANDIDATE
FOR PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (ACM)
* LEXEO THERAPEUTICS - LONG-TERM SAFETY AND EFFICACY WILL BE
EVALUATED FOR AN ADDITIONAL FOUR YEARS FOLLOWING COMPLETION OF
INITIAL TRIAL
Source text for Eikon: ID:nGNX2LpDG5
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease